TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06032975

Intervention type: OTHER
Intervention: Questionnaires
Description: The PROFFIT questionnaire is a PRO instrument composed by 16 items encompassing all the major life domains where FT can be expressed and is formed by two type of items: (1) outcome (items 1-7) and (2) determinants (items 8-16); EORTC QLQ-C30 questionnaire (items 29-30) and OV28 (items 55-58); PRO-CTCAE: short list of 43 symptoms relevant for ovarian cancer

Intervention type: OTHER
Intervention: Questionnaires
Description: The PROFFIT questionnaire is a PRO instrument composed by 16 items encompassing all the major life domains where FT can be expressed and is formed by two type of items: (1) outcome (items 1-7) and (2) determinants (items 8-16); EORTC QLQ-C30 questionnaire (items 29-30) and OV28 (items 55-58); PRO-CTCAE: short list of 43 symptoms relevant for ovarian cancer

Intervention type: OTHER
Intervention: Questionnaires
Description: The PROFFIT questionnaire is a PRO instrument composed by 16 items encompassing all the major life domains where FT can be expressed and is formed by two type of items: (1) outcome (items 1-7) and (2) determinants (items 8-16); EORTC QLQ-C30 questionnaire (items 29-30) and OV28 (items 55-58); PRO-CTCAE: short list of 43 symptoms relevant for ovarian cancer

Intervention type: OTHER
Intervention: Questionnaires
Description: The PROFFIT questionnaire is a PRO instrument composed by 16 items encompassing all the major life domains where FT can be expressed and is formed by two type of items: (1) outcome (items 1-7) and (2) determinants (items 8-16); EORTC QLQ-C30 questionnaire (items 29-30) and OV28 (items 55-58); PRO-CTCAE: short list of 43 symptoms relevant for ovarian cancer
Study: NCT06241976

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose drink
Description: 75g glucose in 300 ml water (281 kcal) used for oral glucose tolerance test (OGTT)

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose drink
Description: 75g glucose in 300 ml water (281 kcal) used for oral glucose tolerance test (OGTT)

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose drink
Description: 75g glucose in 300 ml water (281 kcal) used for oral glucose tolerance test (OGTT)

Intervention type: OTHER
Group type: OTHER
Intervention: Pure orange juice
Description: 300ml pure orange juice (OJ, Tesco 100% Pure Squeezed Orange Juice Smooth containing 129 kcal, 30 g sugar, 0.3 g fibre, 1.8 g protein and 90 mg vitamin C) from Tesco supermarket

Intervention type: OTHER
Group type: OTHER
Intervention: Pure orange juice
Description: 300ml pure orange juice (OJ, Tesco 100% Pure Squeezed Orange Juice Smooth containing 129 kcal, 30 g sugar, 0.3 g fibre, 1.8 g protein and 90 mg vitamin C) from Tesco supermarket

Intervention type: OTHER
Group type: OTHER
Intervention: Pure orange juice
Description: 300ml pure orange juice (OJ, Tesco 100% Pure Squeezed Orange Juice Smooth containing 129 kcal, 30 g sugar, 0.3 g fibre, 1.8 g protein and 90 mg vitamin C) from Tesco supermarket
Study: NCT05347953

Intervention type: DEVICE
Intervention: Single night downgraded home polygraphy
Description: All patients will be outfitted with the ambulatory downgraded polygraphy device (Nox A1, Nox Medical Global, Reykjavik) for 24 hour monitoring. The data exported by the polygraphy device is in European Data Format and will be filtered and annotated using custom MATLAB-software.
Study: NCT04810078

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab and rHuPH20
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab and rHuPH20
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab and rHuPH20
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT06547359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obicetrapib 10mg
Description: tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obicetrapib 10mg
Description: tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe 10mg
Description: tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe 10mg
Description: tablets
Study: NCT05922098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Texture Modified Foods Manual for chewing dysfunctions in older adult
Description: Texture Modified Foods Manual for chewing dysfunctions (including IDDSI)
Study: NCT06059001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMO-103
Description: Investigational Product: 35 mg/mL (4.5 mL/vial) concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: IV infusion - Standard of Care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion - Standard of Care
Study: NCT05304962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGT-419B
Description: oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGT-419B in combination with hormonal therapy
Description: RGT-419B in combination with hormonal therapy (Selective Estrogen Receptor Degrader, Selective Estrogen Receptor Modulator, or Aromatase Inhibitor)
Study: NCT04319276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium maltolate (500 mg)
Description: This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium maltolate (1,000 mg)
Description: This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium maltolate (1,500 mg)
Description: This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium maltolate (2,000 mg)
Description: This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium maltolate (2,500 mg)
Description: This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium maltolate (recommended phase 2 dose)
Description: The maximum-tolerated dose (recommended phase 2 dose).
Study: NCT06451770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERVE-201
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERVE-201
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERVE-201
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERVE-201
Description: Intravenous (IV) infusion
Study: NCT05703256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amygdala real-time fMRI neurofeedback
Description: Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham feedback
Description: Participants are shown activity from another participant's left amygdala who previously completed the task and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
Study: NCT04220190

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RAPA-501 Autologous T cells
Description: TREG/Th2 cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RAPA-501 Autologous T cells
Description: TREG/Th2 cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RAPA-501 Autologous T cells
Description: TREG/Th2 cells
Study: NCT05861180

Intervention type: DEVICE
Intervention: inclinometer, smart phone goniometer and laser beam
Description: devices to objectively assess proprioception of the neck

Intervention type: DEVICE
Intervention: inclinometer, smart phone goniometer and laser beam
Description: devices to objectively assess proprioception of the neck

Intervention type: DEVICE
Intervention: inclinometer, smart phone goniometer and laser beam
Description: devices to objectively assess proprioception of the neck

Intervention type: DEVICE
Intervention: inclinometer, smart phone goniometer and laser beam
Description: devices to objectively assess proprioception of the neck
Study: NCT06497036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP404141
Description: subcutaneous injection
Study: NCT04220190

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RAPA-501 Autologous T cells
Description: TREG/Th2 cells
Study: NCT05181475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oligomannate Capsules (GV-971)
Description: Sodium Oligomannate Capsules, each capsule contains 150 mg of sodium oligomannate. The recommended treatment is oral administration, 450 mg (3 capsules) per dose, bid, in morning and evening.
Study: NCT06446778

Intervention type: DEVICE
Intervention: Pipeline embolization device with or without shield technique
Description: The patients undenwent Pipeline embolization device implantation with or without shield technique due to market availability, choice and preferences of the surgeon.

Intervention type: DEVICE
Intervention: Pipeline embolization device with or without shield technique
Description: The patients undenwent Pipeline embolization device implantation with or without shield technique due to market availability, choice and preferences of the surgeon.
Study: NCT05441449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling Vest
Description: A self-regulating cooling vest for persons with SCI that can utilize both conductive and evaporative methods to dissipate body heat as a proof-of-concept to prevent an excessive rise in Tcore and thermal discomfort during a controlled exposure to a warm environment. The vest is an article of clothing, is made of commercially-available wicking material, which once saturated with water, uses evaporation to dissipate heat. Channels embedded in the vest supply cooled water to keep the wet vest cool. The cooling capacity of the vest is regulated by a microprocessor which continuously receives feedback from the user's skin and core temperature. The vest is non-invasive and supplies no energy to the user.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling Vest
Description: A self-regulating cooling vest for persons with SCI that can utilize both conductive and evaporative methods to dissipate body heat as a proof-of-concept to prevent an excessive rise in Tcore and thermal discomfort during a controlled exposure to a warm environment. The vest is an article of clothing, is made of commercially-available wicking material, which once saturated with water, uses evaporation to dissipate heat. Channels embedded in the vest supply cooled water to keep the wet vest cool. The cooling capacity of the vest is regulated by a microprocessor which continuously receives feedback from the user's skin and core temperature. The vest is non-invasive and supplies no energy to the user.
Study: NCT06568536

Intervention type: OTHER
Intervention: Repeated behavioral assessments, functional electroencephalography and brain imagery, TMS-EEG
Description: The presence of consciousness will be classified considering the highest level of consciousness revealed by repeated behavioral examinations, functional electroencephalography (task-based EEG), and functional brain imagery (task-based fMRI). Based on the results of this composite standard reference, we will evaluate the diagnostic and prognostic accuracy of TMS-EEG measurements of brain complexity
Study: NCT06497036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nplate
Description: subcutaneous injection
Study: NCT05919199

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06007248

Intervention type: DIAGNOSTIC_TEST
Intervention: Protocol-defined Examinations
Description: Lab tests (blood and urine and stool routine tests, hepatic and renal and thyroid function tests, tests for metabolic markers, tests for cardiac biomarkers, thrombosis-related tests, rheumatology tests, tests for inflammation markers), electrocardiography, echocardiography, Birmingham Vasculitis Activity Score (BVAS-3), 6-minute walk test, 1-minute squat test, vascular ultrasound, fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT), coronary angiography, optical coherence tomography (OCT), tests for exploratory biomarkers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Protocol-defined Examinations
Description: Lab tests (blood and urine and stool routine tests, hepatic and renal and thyroid function tests, tests for metabolic markers, tests for cardiac biomarkers, thrombosis-related tests, rheumatology tests, tests for inflammation markers), electrocardiography, echocardiography, Birmingham Vasculitis Activity Score (BVAS-3), 6-minute walk test, 1-minute squat test, vascular ultrasound, fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT), coronary angiography, optical coherence tomography (OCT), tests for exploratory biomarkers.
Study: NCT05965466

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal gastrectomy and radical resection
Description: Distal gastrectomy and Roux-en-Y anastomosis

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Total gastrectomy and radical resection
Description: Total gastrectomy and Roux-en-Y anastomosis
Study: NCT05432960

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RPH-104
Description: solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline (0.9% Sodium Chloride solution)
Study: NCT06083493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIFUP excitation
Description: The experimental will consist of a 10-minute baseline period (LIFUP-OFF) followed by four 10-minute sessions of stimulating (LIFUP-ON-excitation) four thalamic areas. The order of thalamic area stimulation will be counterbalanced across participants and will include the ventral anterior (VA), dorsal anterior (DA), ventral posterior (VP), and dorsal posterior (DP) sections of the thalamus.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIFUP inhibition
Description: The experimental will consist of a 10-minute baseline period (LIFUP-OFF) followed by four 10-minute sessions of stimulating (LIFUP-ON-inhibition) four thalamic areas. The order of thalamic area stimulation will be counterbalanced across participants and will include the ventral anterior (VA), dorsal anterior (DA), ventral posterior (VP), and dorsal posterior (DP) sections of the thalamus.
Study: NCT04702672

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100% wheat (control)
Description: Intake of 250 ml of tap water and 100 g of bread baked with 100% wheat flour (regular commercial available wheat flour). Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100% wheat (control)
Description: Intake of 250 ml of tap water and 100 g of bread baked with 100% wheat flour (regular commercial available wheat flour). Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100% Lean-baking barley®
Description: Intake of 250 ml of tap water and 100 g of bread baked with 100% Lean-baking barley® flour. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.~HIAMBA® are naturally bred in corporation with PlantCarb ApS and researchers at Aarhus and Copenhagen Universities. The wheat flour is standard commercial available flou

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100% Lean-baking barley®
Description: Intake of 250 ml of tap water and 100 g of bread baked with 100% Lean-baking barley® flour. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.~HIAMBA® are naturally bred in corporation with PlantCarb ApS and researchers at Aarhus and Copenhagen Universities. The wheat flour is standard commercial available flou

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100% regular barley
Description: Intake of 250 ml of tap water and 100 g of bread baked with 100% regular barley flour and 25% wheat flour. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.~HIAMBA® are naturally bred in corporation with PlantCarb ApS and researchers at Aarhus and Copenhagen Universities. The wheat flour is standard commercial available flour.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100% regular barley
Description: Intake of 250 ml of tap water and 100 g of bread baked with 100% regular barley flour and 25% wheat flour. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.~HIAMBA® are naturally bred in corporation with PlantCarb ApS and researchers at Aarhus and Copenhagen Universities. The wheat flour is standard commercial available flour.
Study: NCT05290818

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAKO™ Partial Knee Arthroplasty
Description: The robotic-arm will be used to position a partial knee arthroplasty.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon (Stryker) Total Knee Arthroplasty
Description: Triathlon (Stryker) TKA with a cruciate retaining polyethylene insert.
Study: NCT04650841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Cream with Naloxone
Description: Participants will be informed that the spray is an effective pain and negative emotion reducing agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control Cream with Naloxone
Description: Participants will be informed that the spray is saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Cream with Saline
Description: Participants will be informed that the spray is an effective pain and negative emotion reducing agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control Cream with Saline
Description: Participants will be informed that the spray is saline.
Study: NCT04900935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POISE
Description: POISE (Patient-centered, Optimal Integration of Survivorship and palliative carE) is a brief, population-specific intervention that consists of four sessions with palliative care specialists who have been additionally trained to evaluate and address the specific psychosocial issues and health-promoting behaviors of patients with long, uncertain cancer trajectories.
Study: NCT06246721

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-management of vaginal pessary
Description: Self-management of vaginal pessary

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Self-management of vaginal pessary
Description: Self-management of vaginal pessary
Study: NCT06009978

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular electrical stimulation (NMES)
Description: Neuromuscular electrical stimulation (NMES) 2 times a day á 15 minutes from the third to the eight week after injury. The additional treatment will be perform in the patients home by themselves
Study: NCT06342960

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KYV-101 anti-CD19 CAR-T cell therapy
Description: KYV-101 anti-CD19 CAR-T cell therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KYV-101 anti-CD19 CAR-T cell therapy
Description: KYV-101 anti-CD19 CAR-T cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard lymphodepletion regimen
Description: Standard lymphodepletion regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard lymphodepletion regimen
Description: Standard lymphodepletion regimen
Study: NCT05035927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRYP-0082
Description: A single (1) 25 mg oral dose of TRP 8802 will be administered in a carefully monitored setting following 6 to 8 hours of preparatory psychotherapy. Subjects will be in the study for 12 weeks following the dose of TRP 8802 (until Week 14), approximately 5 months from initiation of screening through the last follow-up.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: A single (1) 25 mg oral dose of TRP 8802 will be administered in a carefully monitored setting following 6 to 8 hours of preparatory psychotherapy. Subjects will be in the study for 12 weeks following the dose of TRP 8802 (until Week 14), approximately 5 months from initiation of screening through the last follow-up.
Study: NCT06359561

Intervention type: DEVICE
Intervention: cervical lead placement
Description: implant of cervical lead neurostimulation, using saluda medical devices
Study: NCT05257018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CDOP+intrathecal MTX
Description: R-CDOP+intrathecal MTX：~* Rituximab 375 mg / m\^2，D1~* Cyclophosphamide 750 mg / m\^2，D2~* Doxorubicin Hydrochloride Liposome Injection 35mg / m\^2，D2~* Vincristine 1.4mg/m\^2 (dose capped at 2 mg)，D2~* Prednisone 50 mg， bid D2-6~* Cycle1-5：Intrathecal MTX 12 mg + DXM 5 mg after chemotherapy （PK patients will be given 24 h after chemotherapy）
Study: NCT06262997

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates
Description: Pilates training will be given to groups of 3 people for 8 weeks, 2 days a week. Exercises will start with 10-12 repetitions and the number of repetitions will be increased to 20 starting from the 4th week. Before the Pilates training, basic principles such as breathing, concentration, focusing on the center, control, precision and fluid movement will be taught in a special session to inform individuals about the training principles and exercises. Each exercise will be demonstrated by the physiotherapist and cues such as tactile, verbal and imagery will be used to control the participants throughout the training. The difficulty level of Pilates training will be progressed by changing body positions, exercise ball and band use according to the performance of the patients and Pilates principles. The exercise program will start with warm-up exercises and end with 40 minutes of basic Pilates exercises followed by cooling exercises.